Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.23 USD | +2.53% |
|
-24.69% | +72.97% |
20/06 | Top Premarket Gainers | MT |
17/06 | Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+72.97% | 24Cr | - | ||
+15.20% | 12TCr | B+ | ||
+19.67% | 11TCr | B+ | ||
+18.95% | 2.65TCr | B | ||
-23.86% | 1.94TCr | B+ | ||
-19.03% | 1.62TCr | A- | ||
-20.90% | 1.54TCr | B | ||
-46.14% | 1.52TCr | A- | ||
+63.85% | 1.49TCr | C+ | ||
+4.49% | 1.35TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MOLN Stock
- MOLN Stock
- Ratings Molecular Partners AG